FDA Delays Final OK for Type 2 Drug Empagliflozin
The FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until "previously observed deficiencies" at the plant where it is manufactured are fixed.
The delay does not call into question the safety or utility of the drug, which is manufactured by Eli Lilly and Boehringer Ingelheim.
<-- Gary VandenBergh of Cresskill is fighting to focus more attention on diabetes
New test to deduce diabetes risk in polycystic ovary syndrome sufferers -->